content_copy Vitro Biopharma Retains Leading Health Care Executive as Acting Direct

Vitro Biopharma Retains Leading Health Care Executive as Acting Director of Regulatory Affairs & Director

August 20, 2021

Regulatory affairs

Vitro Biopharma Retains Leading Health Care Executive as Acting  Director of Regulatory Affairs & Director 

Golden, Colorado-April 3, 2021-Vitro Biopharma, Inc. (formerly Vitro Diagnostics, Inc.)  announced the appointment of Dr. Caroline Mosessian, PhD, DRSc, FACMPE, ACHE as its  acting Director of Regulatory Affairs. Dr. Mosessian has an extensive background in regulatory  science including a PhD, MS and Masters in Healthcare Administration degrees from USC in  LA. In 2016 she was honored with the prestigious Top Ranked US Executive Award awarded to  the top 1% of the millions of active executives in the United States. She is a trusted advisor for  strategic development and operations to a variety of technology firms promoting innovation  excellence to enhance quality of life for patients, caregivers and providers while optimizing  outcomes and overall corporate success. In addition to regulatory expertise, she has extensive  experience in the development, management and licensing of intellectual property, government  and private fund raising, strategic planning and clinical research operations. She is fluent in  several languages that support her international business development skills. She is also actively  involved in local, national and international charitable organizations that emphasize  humanitarian aid. 

She has led numerous clinical studies of medical devices and pharmaceuticals through  regulatory agency approval including the FDA and EMA leading to successful development of  multi-million dollar clinical programs. She presently assists Vitro Biopharma in the guidance,  drafting and submission of its pending IND phase I application to the FDA (Randomized,  Double-blinded, placebo-controlled study of the safety and efficacy of therapeutic treatment with AlloRx Stem Cells® in adults with COVID-19). As a result, the FDA has authorized  several expanded access/compassionate use INDs that employ IV infusion of AlloRx Stem  Cells in the treatment of COVID-19 patients. 

These results together with several additional clinical studies using MSCs are now providing  substantial clinical evidence of safety and efficacy of stem cell therapy for COVID-19.  Furthermore, since MSC therapy is independent of the genome of the virus, this MSC therapy is likely to be effective in treatment of COVID-19 patients infected with new variants resulting  from viral mutation. 

Dr. Jack Zamora, MD and CEO said, “We are elated to add Dr Mosessian to our regulatory team targeting FDA approval of AlloRx Stem Cells®. She has been instrumental in establishing a  strong working relationship between Vitro Biopharma and the FDA. She will also be a key  driver of the execution of our pending Phase I trial and future INDs targeting additional  indications of AlloRx Stem Cells®.” 

Dr. Mosessian said, "I am inspired by Vitro Biopharma's mission to deliver innovative solutions  and access to regenerative therapies to deliver unmet needs of the vulnerable patients. I feel  fortunate to become part of the team thriving to achieve such an ambitious goal."

John Evans C.F.O. and Chairman of the Board said “ We are pleased to have Caroline join the Board of Directors of the company, she adds such a wide breadth of experience in the regulatory,  clinical and legal areas of board governance. 


Out of years of research, we developed our patent-pending and proprietary line of umbilical cord  derived stem cells AlloRx Stem Cells® now being used in offshore regenerative medicine  clinical trials. Our stem cells are used in regenerative medicine clinical trials with our partner in  the Cayman Islands We have a recently approved clinical trial using  our AlloRx Stem Cells® to treat musculoskeletal conditions at The Medical Pavilion of the  Bahamas in Nassau. Our nutraceutical stem cell activation product,  Stemulife™ complements AlloRx Stem Cells® as an adjuvant therapy to optimize therapeutic  outcomes. 

Vitro Biopharma has a proprietary and scalable manufacturing platform to provide stem cell  therapies to critically ill Coronavirus patients and other conditions including multiple sclerosis,  OA, Chrohn’s disease, and numerous medical conditions that are under-treated by the current  standard of care. Our cGMP manufacturing is CLIA, ISO9001, ISO13485 certified and we are  FDA registered. Our stem cells have been shown to be safe and effective in Phase I clinical  trials. 

Forward-Looking Statements 

Statements herein regarding financial performance have not yet been reported to the SEC nor  reviewed by the Company’s auditors. Certain statements contained herein and subsequent  statements made by and on behalf of the Company, whether oral or written may contain  “forward-looking statements”. Such forward-looking statements are identified by words such as  “intends,” “anticipates,” “believes,” “expects” and “hopes” and include, without limitation,  statements regarding the Company’s plan of business operations, product research and  development activities, potential contractual arrangements, receipt of working capital,  anticipated revenues, and related expenditures. Factors that could cause actual results to differ  materially include, among others, acceptability of the Company’s products in the market place,  general economic conditions, receipt of additional working capital, the overall state of the  biotechnology industry and other factors set forth in the Company’s filings with the Securities  and Exchange Commission. Most of these factors are outside the control of the Company.  Investors are cautioned not to put undue reliance on forward-looking statements. Except as  otherwise required by applicable securities statutes or regulations, the Company disclaims any  intent or obligation to update publicly these forward-looking statements, whether as a result of  new information, future events or otherwise. 


Dr. Jack Zamora, MD 

Chief Executive Officer 

Vitro Biopharma, Inc.

(303) 999-2130 x 1 

Source: Vitro Biopharma, Inc.

Also in News

Pitt Hopkins FDA Trial
Vitro Biopharma Receives FDA Authorization to Conduct a Clinical Trial Using AlloRx Stem Cells® to Treat Pitt Hopkins Syndrome, a rare form of Autism

November 18, 2021 0 Comments

Golden, Colorado-November 9, 2021- Vitro Biopharma, Inc. announced receipt of FDA authorization and clearance to enroll patients in its IND for a phase I-II, randomized, double-blind, placebo-controlled study of the safety and efficacy of therapeutic treatment with AlloRx Stem Cells® in children with Pitt Hopkins Syndrome (PTHS), a rare neurogenetic disorder that features autistic traits. PTHS results from genetic mutations/deletions of a key brain development gene, TCF4 (transcription factor 4) that controls neurogenesis. 

Read More

Fitore and Infinivive logo
Vitro Biopharma Acquires Fitore Nutrition and Infinivive MD, Adding Revenues from Innovative Stem Cell Activation Products and Topical Cosmetic Stem Cell Serums

August 31, 2021 0 Comments

Golden, Colorado-August 31, 2021- Vitro Biopharma, Inc. ("Vitro') announced the acquisition of Fitore Nutrition ("Fitore") and Infinivive MD ("Infinivive"). Fitore, a private company headquartered in Denver, Colorado creates clinically validated supplements and sells them direct to consumers (D2C) via their unique digital marketing platform and SEO expertise.

Infinivive, located in Cherry Creek, Colorado developed the world's first topical cosmetic stem cell serum and is a nationally recognized company led by one of the top industry pioneers in the area of cosmetic surgery, Dr. Jack Zamora M.D.

Read More

Vitro Biopharma Signs Multi-Million Dollar Operating Service Contract with European Wellness Biomedical Group
Vitro Biopharma Signs Multi-Million Dollar Operating Service Contract with European Wellness Biomedical Group

August 20, 2021 0 Comments

Golden, Colorado-August 19, 2021-Vitro Biopharma, Inc. announced the signing of a contract with European Wellness Biomedical Group headquartered in Kuala Lumpur, Malaysia and it’s start-up subsidiary BioPep being registered in Delaware, USA to develop FDA-approval of biological products derived from existing mitochondrial peptide extracts now used globally as treatment of various conditions including aesthetic dermatology and skin revitalization, autism spectrum disorders, cardiovascular, metabolic and degenerative disorders, CKD and fertility through its global network of 12 (twelve) biomedical regenerative centers located throughout Europe and Asia Pacific. 

Read More